This is a routine ownership update with no activist escalation. Monitor the company's post-private placement cash position and any strategic transaction announcements, as the 10-K noted plans for a Post-Investment Transaction.
Price Chart
Executive Summary
Junyi Dai, CEO and Chairman of Indaptus Therapeutics, filed Amendment No. 3 to Schedule 13D reporting a passive decrease in beneficial ownership from 7.325% to 7.325% of common stock, solely due to dilution from the company's October 16, 2026 private placement of 20,338,974 shares. Dai did not acquire or dispose of any shares; his 11,250,000 shares (acquired via conversion of Series AA and AAA Preferred Stock on March 23, 2026) remain unchanged. The filing is a routine ownership update with no change in purpose or demands.
Key Financial Metrics
Key Facts
- Junyi Dai beneficially owns 11,250,000 shares of common stock, unchanged from prior filing.
- Percentage ownership decreased from 7.325% to 7.325% due solely to the issuance of 20,338,974 new shares in the October 16, 2026 private placement.
- Dai is CEO and Chairman of Indaptus Therapeutics; his shares were acquired via conversion of Series AA and AAA Preferred Stock on March 23, 2026.
- No transactions in common stock by Dai during the past 60 days.
- Filing is a passive ownership update with no new demands, strategic changes, or escalation.
Financial Impact
No direct financial impact; ownership percentage diluted by ~0.0% (from 7.325% to 7.325%) due to share issuance.
Risk Factors
- Dilution from the October 2026 private placement may pressure the stock.
- No change in insider conviction or demands; the filing provides no new catalyst.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D/A Filing (Primary) | 0001829126-26-011444 |
| Document: 0001829126-26-011444-index.html | 0001829126-26-011444 |
| Document: 0001829126-26-011444.txt | 0001829126-26-011444 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | SC 13D/A | $3.16 | awaiting T+60 | — | $3.47 (+9.78%) |
Oct 22, 2026 4d ago | SC 13D/A | $3.16 | awaiting T+60 | — | $3.47 (+9.78%) |
Oct 22, 2026 4d ago | SC 13D/A | $3.16 | awaiting T+60 | — | $3.47 (+9.78%) |
Oct 21, 2026 5d ago | SC 13D/A | $2.99 | awaiting T+60 | — | $3.47 (+16.02%) |
Oct 20, 2026 6d ago | 8-K | $3.16 | awaiting T+60 | — | $3.47 (−9.78%) |
Sep 30, 2026 27d ago | 8-K | $2.30 | awaiting T+60 | — | $3.47 (+50.83%) |
Sep 9, 2026 6w ago | 8-K | $2.56 | awaiting T+60 | — | $3.47 (−35.51%) |
Sep 4, 2026 7w ago | 424B5 | $1.85 | awaiting T+60 | — | $3.47 (−87.51%) |
Sep 1, 2026 8w ago | 8-K | $1.13 | awaiting T+60 | — | $3.47 (−206.99%) |
Aug 26, 2026 8w ago | EFFECT | $1.14 | awaiting T+60 | — | $3.47 (−204.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers